


INTRODUCTION

New Psychoactive Substances (NPS) are constantly being developed as legal substitution of traditional drugs of abuse. Although the traditional drugs maintain popular, new drugs are regularly introduced, changing the drug market ceaselessly [1]. Monitoring NPS and its consumption is challenging as these compounds are normally missed in routine drug analysis, users do often not exactly know what they consume and information available is limited of what is being sold. Furthermore, very little information exists on metabolism of these newly introduced NPS [2]. This highlights the need of applying a strategic workflow making use of modern analytical techniques to face this novel public health challenge. The workflow presented in this work consists of three stages: i) The creation of a database with around 200 NPS, including NPS recently reported to the National Early Warning Systems (EWS) of Spain and Italy and the EWS of the European Monitoring Center for Drugs and Drug Addiction (EMCDDA). ii) The collection of urine samples of individuals suspected of drug consumption, pooled urine samples from festivals and urban wastewater samples. iii) The screening of NPS using ultra-high performance liquid chromatography coupled to high resolution mass spectrometry with a hybrid quadrupole time-of-flight mass analyzer.

Although the database is under constant development, including NPS reported to be present in wastewaters around Europe, new compounds appearing in the market, as well as metabolites reported in the literature, the workflow applied allowed the detection of several unchanged NPS in urine and wastewater samples, which indicates that consumption of some of these compounds is a reality. The absence of reference standards for several NPS found, as well as for some NPS metabolites, made it unfeasible the full confirmation of some compounds in the urine/wastewater samples analyzed. However, accurate-mass full-spectrum data provided by HRMS allowed their detection / identification with high degree of reliability. The subsequent acquisition of reference standards, when available, will allow the unequivocal confirmation of their identity.

1) Database creation



2) Sample collection

- Collection of Urine samples of potential consumers:
 - Emergency Rooms and Drug Addiction Treatment Departments: individual urine samples from suspect consumers
 - Music festivals:
 - Pooled urine samples from volunteers
 - Pooled urine samples from portable toilets
- Collection of Urban Wastewater:
 - Pooled Urban Wastewater collected during local festivities



3) Screening of NPS

SAMPLE TREATMENT	INSTRUMENTATION (UHPLC- QTOF MS)	SCREENING CRITERIA
<p>Individual urines from Hospitals</p> <ul style="list-style-type: none"> Hydrolysis <p>Pooled urines from Music Festivals</p> <ul style="list-style-type: none"> Hydrolysis HLB SPE MCX SPE <p>Urban Wastewater</p> <ul style="list-style-type: none"> HLB SPE MCX SPE 	<p>UHPLC (Acquity UHPLC, Waters)</p> <p>Column: Cortecs® C18 2.7µm 2.1x100 mm</p> <p>Mobile phase: A: H₂O 0.01% HCOOH B: MeOH 0.01% HCOOH</p> <p>Flow: 0.3 mL min⁻¹</p> <p>Volume injection: 20 µL</p> <p>QTOF MS (Xevo G2 QTOF, Waters)</p> <p>ESI+ mode</p> <p>Acquisition Mass range: 50 to 1000 m/z units</p> <p>Sampling cone: 25 V</p> <p>MSⁿ: Low Energy Function (LE): 4 eV High Energy Function (HE): 10-40 eV</p> <p>Capillary voltage: 0.7 kV</p> <p>Source Temperature: 130 °C</p>	<p>Screening parameters [3]:</p> <p>Retention time (Rt) – Accurate m/z ions – Mass errors – Isotope pattern (Cl, Br...)</p> <p>Standard available</p> <ul style="list-style-type: none"> Detection <ul style="list-style-type: none"> OPTION 1: Rt agreement, One ion (Q), Mass error < 5 ppm, Isotope pattern OPTION 2: Rt agreement, Two ions (Q and q), Mass error > 5 ppm, Isotope pattern Identification: Rt agreement, Two ions (Q and q), Q mass error < 5 ppm, q mass error < 5 ppm <p>Standard unavailable</p> <ul style="list-style-type: none"> Tentative identification: Expected ion (Q) present with mass error < 5 ppm, Compatible isotopic pattern (Cl, Br...), One or more fragment ions (q), In agreement with data reported, compatible with the chemical structure of the candidate (mass error < 5 ppm) <p>Confirmation required with reference standard</p>

SCREENING ANALYSIS

4-Methylethcathinone (4-MEC)

Recreational psychostimulant
Alert released in March 2010 by EMCDDA [4]
Submitted to control and criminal penalties in EU in December 2010 [4]

Found in Pooled Urine Sample from Music Festivals

Confirmed

Methoxetamine (MXE)

Found in Individual Urine Sample from Hospital

Ketamine analogue
Health and social risks assessed by EMCDDA in April 2014 [5]
Several intoxications across EU reported in 2014 [5]

Tentatively Identified

4-MEC Standard

Rt = 3.66 min

RESULTS

Individual Urines from Hospitals	Pooled Urines from Music Festivals	Urban Wastewater
<ul style="list-style-type: none"> Methoxetamine (MXE) 	<ul style="list-style-type: none"> 3-methylmethcathinone (3-MMC) 4-fluoromethcathinone (4-FMC) 4-methylethcathinone (4-MEC) 	<ul style="list-style-type: none"> Mephedrone (4-MMC) Methylone Butylone
<ul style="list-style-type: none"> 3,4-dimethoxy-α-PVP 4-methylmethylphenidate α-methyltryptamine 	<ul style="list-style-type: none"> 3,4-dimethoxy-α-PVP (3-MeOMC) 3-methoxymethcathinone (3-MeOMC) bk-DMBP (Dipentylone) α-methyltryptamine α-PVP 4'-chloro-α-PPP 	<ul style="list-style-type: none"> p-methoxymethamphetamine (PMMA) 2-phenethylamine

CONCLUDING REMARKS

- A database containing more than 200 recently seized compounds was created based on the information provided by different national and international authorities.
- Approximately 1000 samples were collected with an strategic sampling process in locations with high probability of NPS consumption.
- A total of 19 NPS were found in urine samples from hospitals and music festivals and in urban wastewater.
- The majority of NPS detected were cathinones (62%) which agrees with reports of EMCDDA on NPS consumption.
- No synthetic cannabinoids were found. Probably, this was due to the fact that these type of compounds are highly metabolised and therefore no 'original' compound is excreted.

REFERENCES

- Reid, M. and Thomas, K. (2016), 'New psychoactive substances: analysis and site-specific testing', pp. 57–65 in Assessing illicit drugs in wastewater: advances in wastewater-based drug epidemiology, EMCDDA Insights 22, Publications Office of the European Union, Luxembourg.
- European Monitoring Centre for Drugs and Drug Addiction and Europol (2016), EU Drug Markets Report: In-Depth Analysis, EMCDDA–Europol Joint publications, Publications Office of the European Union, Luxembourg.
- Hernández, F., Castiglioni, S., Covaci, A., de Voogt, P., Emke, E., Kasprzyk-Hordern, B., Ort, C., Reid, M., Sancho, J.V., Thomas, K.V., van Nuijs, A.L.N., Zuccato, E., Bijlsma, L., Mass spectrometric strategies for the investigation of biomarkers of illicit drug use in wastewater, Mass Spectrom. Rev. (2016). doi:10.1002/mas.21525
- European Monitoring Centre for Drugs and Drug Addiction, Europol – EMCDDA Joint Report on a new psychoactive substance: 4-methylethcathinone., 2010.
- European Monitoring Centre for Drugs and Drug Addiction, Methoxetamine – Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances, 2014. doi:10.2810/44197.

ACKNOWLEDGEMENTS

The authors acknowledge the financial support of NPS-Euronet (HOME/2014/JDRUG/AG/DRUG/7086), co-funded by the European Union. Dr. Lubertus Bijlsma acknowledges NPS-Euronet (HOME/2014/JDRUG/AG/DRUG/7086), co-funded by the European Union, for his post-doctoral fellowship. Dr. Félix Hernández acknowledges the Spanish Ministry of Economy and Competitiveness for financial support in the field of illicit drug research (Ref. CTQ2015-65603-P). Alberto Celma acknowledges the Spanish Ministry of Economy and Competitiveness for his predoctoral grant (Ref. BES-2016-076914). This publication reflects the view only of the authors, and the European Commission and Spanish Ministry of Economy and Competitiveness can not be held responsible for any use which may be made of the information contained therein.